Elkar Injection 100mg / 5ml ampoules 10 mL pc

Description

Composition
Active substance:
1 ml of solution contains: L-carnitine (Karnif) – 0.1 g ;.
Excipients:
Water for injection – up to 1 ml.
Description:
Transparent colorless liquid.
Product form:
Solution for intravenous and intramuscular administration of 100 mg / ml. 5 ml of the product in clear glass ampoules of a ring or a break-point. 10 ampoules were placed in a pack with baffles. Or 5 ampoules were placed in blisters of PVC film. Two contour package is placed in a pile of cardboard. In each pack put on the drug instruction. Packing for the hospital. 10 or 20 contour of cellular packages placed in a box made of cardboard or corrugated cardboard. Each box was placed on a number of operation instructions equal to the number of contour of cellular packages.
Contraindications
Individual intolerance, pregnancy, lactation period (currently there is no data on the feasibility and safety of the drug during pregnancy and lactation).
Dosage
100 mg / ml
Indications
Elkar is used in the complex therapy of acute hypoxic conditions (acute brain hypoxia, ischemic stroke, transient ischemic attack). Drug administered in the acute, subacute and recovery period of cerebral blood flow. Applied with vascular encephalopathy and various toxic and traumatic brain lesions in the recovery period after surgery. Elkar is indicated for primary and secondary carnitine deficiency, including patients with chronic renal failure on hemodialysis; with cardiomyopathy, ischemic heart disease (angina pectoris, acute myocardial infarction, postinfarction state), hypoperfusion due to cardiogenic shock and other disturbances in the metabolism of the myocardium.
Interaction with other drugs
Glucocorticosteroids promote accumulation of the drug in the tissues (except liver), other anabolic agents enhance the effect.
pharmachologic effect
Pharmacological group:
Metabolic means.
Pharmacodynamics:
Elkar – means for correction of metabolic processes. L-carnitine (natural substance related vitamins of group B) is involved in metabolic processes as a carrier of fatty acids across the cell membrane from the cytoplasm to mitochondria, where the acids are oxidized (the process of beta-oxidation) to form a large amount of metabolic energy (in the form of ATP ). L-carnitine increases the resistance of the nerve tissue to damaging factors (hypoxia, trauma, intoxication et al.), Inhibits the formation of keto acid and anaerobic glycolysis, reduces the degree of lactic acidosis. The drug blood fills the alkaline reserve, the recovery of autoregulation of cerebral hemodynamics and increase blood supply to the affected area, accelerates reparative processes in the lesion and has anabolic effects.
Pharmacokinetics:
After the on / in 3 hours almost completely cleared from the blood. Easily penetrates the liver and myocardium, slower – in the muscles. Predominantly excreted by the kidneys in the form of esters of acyl (more than 80% in 24 hours).
Conditions of supply of pharmacies
On prescription.
side effects
Allergic reactions, muscle weakness (in patients with uremia). With the rapid introduction (80 drops / min or more) may cause pain along the vein, extending in reducing the rate of administration.
Storage conditions
The protected from light at a temperature not higher than 25 ° C.
Keep out of the reach of children.
Dosing and Administration
One ampoule contains 0,5 g of active ingredient. Elkar® administered intravenously or slow bolus (2-3 minutes) or / m. Before on / in the contents of the ampoule were dissolved in 100-200 ml of solvent (0.9% sodium chloride or 5% dextrose (glucose)). In acute cerebrovascular disorders appoint 1 g / day (2 ampoules) for 3 days and then 0.5 g / day (1 ampoule) for 7 days. After 10-12 days can repeat courses of 3-5 days. When administering the drug in subacute and recovery period, with various vascular encephalopathy and brain lesions, deficiency of carnitine is administered to patients Elkar® solution at the rate of 0.5-1 g / day (1-2 ampoules) intravenously (infusion, bolus) or / m (2-3 times a day) without dilution for 3-7 days. If necessary, after 12-14 days, appoint a second course. Intravenous, slowly (2-3 min) is prescribed for the secondary carnitine deficiency in hemodialysis – 2 g (4 capsules) once (after treatment); during acute myocardial infarction, congestive heart failure – 3-5 g / day (6-10 ampoules), divided into 2-3 hours in the first 2-3 days followed by dose reduction by 2 times; in cardiogenic shock – 3-5 g / day (6-10 ampoules), divided into 2-3 hours until the patient out of shock. Next, moving to Elkar® oral intake.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist